Literature DB >> 30338414

Role of comorbidities in spondyloarthritis including psoriatic arthritis.

Silvia Scriffignano1, Fabio Massimo Perrotta1, Antonia De Socio1, Ennio Lubrano2.   

Abstract

Spondyloartrhitis (SpA) are a group of diseases characterized by inflammation at articular and entheseal sites. Moreover, patients with SpA suffer from impaired articular function and reduced quality of life. Beyond the articular involvement, SpA and in particular psoriatic arthritis (PsA) are associated with extra-articular manifestations and comorbidities that might increase the burden of the disease. The aim of this article was to review the available evidences on the presence of comorbidities in SpA, including PsA, focusing the attention on the cardiovascular, metabolic aspects, as well as other comorbidities, and their possible management in an integrated manner. Comorbidities in SpA should be carefully evaluated because of their important impact.

Entities:  

Keywords:  Ankylosing spondylitis; Comorbidities; Outcome; Psoriatic arthritis; Spondyloarthritis; Treatment

Mesh:

Year:  2018        PMID: 30338414     DOI: 10.1007/s10067-018-4332-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  62 in total

1.  Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level.

Authors:  I Ertenli; S Ozer; S Kiraz; S B Apras; A Akdogan; O Karadag; M Calguneri; U Kalyoncu
Journal:  Rheumatol Int       Date:  2010-11-16       Impact factor: 2.631

Review 2.  Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis.

Authors:  Sylvain Mathieu; Laure Gossec; Maxime Dougados; Martin Soubrier
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

3.  Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis.

Authors:  Chi Chiu Mok; Gary Tin Choi Ko; Ling Yin Ho; Ka Lung Yu; Pak To Chan; Chi Hung To
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-02       Impact factor: 4.794

Review 4.  Inflammation and metabolic disorders.

Authors:  Gökhan S Hotamisligil
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

5.  Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study.

Authors:  Jiunn-Horng Kang; Yi-Hua Chen; Herng-Ching Lin
Journal:  Ann Rheum Dis       Date:  2010-04-07       Impact factor: 19.103

6.  Malignant tumours and psoriasis: a follow-up study.

Authors:  G Frentz; J H Olsen
Journal:  Br J Dermatol       Date:  1999-02       Impact factor: 9.302

7.  The risk of lymphoma in patients with psoriasis.

Authors:  Joel M Gelfand; Daniel B Shin; Andrea L Neimann; Xingmei Wang; David J Margolis; Andrea B Troxel
Journal:  J Invest Dermatol       Date:  2006-06-01       Impact factor: 8.551

Review 8.  Cytokines sing the blues: inflammation and the pathogenesis of depression.

Authors:  Charles L Raison; Lucile Capuron; Andrew H Miller
Journal:  Trends Immunol       Date:  2005-11-28       Impact factor: 16.687

9.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

10.  Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease.

Authors:  S Mathieu; H Joly; G Baron; A Tournadre; J-J Dubost; J-M Ristori; J-R Lusson; M Soubrier
Journal:  Rheumatology (Oxford)       Date:  2008-06-04       Impact factor: 7.580

View more
  8 in total

1.  Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement.

Authors:  Maria Sole Chimenti; Paola Conigliaro; Francesco Caso; Luisa Costa; Augusta Ortolan; Paola Triggianese; Marco Tasso; Giulia Lavinia Fonti; Maria Grazia Lorenzin; Roberto Perricone; Roberta Ramonda
Journal:  Clin Rheumatol       Date:  2021-08-19       Impact factor: 3.650

Review 2.  The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review.

Authors:  Juan D Cañete; Jose Antonio Pinto Tasende; Francisco José Rebollo Laserna; Susana Gómez Castro; Rubén Queiro
Journal:  Rheumatol Ther       Date:  2020-04-08

3.  Immunological risk factors for nonalcoholic fatty liver disease in patients with psoriatic arthritis: New predictive nomograms and natural killer cells.

Authors:  Baochen Li; Rui Su; Huanhuan Yan; Juanjuan Liu; Chong Gao; Xiaofeng Li; Caihong Wang
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

4.  Residual Disease in Patients with Axial Spondyloarthritis: A Post-Hoc Analysis of the QUASAR Study.

Authors:  Salvatore D'Angelo; Carlo Salvarani; Francesca Marando; Giuliana Gualberti; Lucia Novelli; Giacomo Curradi; Giovanni Tripepi; Annalisa Pitino; Roberta Ramonda; Antonio Marchesoni
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

5.  TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA).

Authors:  Nienke J Kleinrensink; Frank T Perton; Juliëtte N Pouw; Nanette L A Vincken; Sarita A Y Hartgring; Mylène P Jansen; Saeed Arbabi; Wouter Foppen; Pim A de Jong; Janneke Tekstra; Emmerik F A Leijten; Julia Spierings; Floris P J G Lafeber; Paco M J Welsing; Marloes W Heijstek
Journal:  BMJ Open       Date:  2022-10-10       Impact factor: 3.006

Review 6.  Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk.

Authors:  Nuria Barbarroja; Miriam Ruiz-Ponce; Laura Cuesta-López; Carlos Pérez-Sánchez; Chary López-Pedrera; Iván Arias-de la Rosa; Eduardo Collantes-Estévez
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

7.  Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study.

Authors:  Ennio Lubrano; Silvia Scriffignano; Ana Belen Azuaga; Julio Ramirez; Juan D Cañete; Fabio Massimo Perrotta
Journal:  Rheumatol Ther       Date:  2020-08-17

8.  Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry.

Authors:  Proton Rahman; Regan Arendse; Majed Khraishi; Dalton Sholter; Maqbool Sheriff; Emmanouil Rampakakis; Allen J Lehman; Francois Nantel
Journal:  BMJ Open       Date:  2020-08-13       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.